(UroToday.com) The practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer session at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), included a presentation by Dr. Declan Murphy who discussed the Impact of the Federal Drug Administration (FDA) approval of PSMA PET/CT in prostate cancer management. The FDA approval was recently granted in the United States (US) for use of PSMA PET/CT, but only at two centers: UCLA and UCSF. Since PSMA PET/CT has been used for many years in Australia, Dr. Murphy is able to provide insights into how utilization of this novel imaging technology may look in the US over the coming months/years (the good, the bad and the ugly!).